CASI Pharmaceuticals Files 6-K with Press Release
Ticker: CASIF · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, sec, press-release
TL;DR
CASI Pharma dropped a 6-K on 11/15/24 with a press release. Check it out.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on November 15, 2024, to report information as a foreign private issuer. The filing includes a press release dated November 15, 2024, as Exhibit 99.1. The company's principal executive office is located in Beijing, People's Republic of China.
Why It Matters
This filing indicates that CASI Pharmaceuticals is providing updated information to the SEC, which could include significant business developments or financial updates relevant to investors.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain any immediately alarming information.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer
- November 15, 2024 (date) — Filing Date
- Beijing, People's Republic of China (location) — Principal Executive Office
- Exhibit 99.1 (document) — Included Press Release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer, including a press release dated November 15, 2024.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on November 15, 2024.
Where is CASI Pharmaceuticals, Inc.'s principal executive office located?
CASI Pharmaceuticals, Inc.'s principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
What exhibit is included with this filing?
Exhibit 99.1, a Press Release of CASI Pharmaceuticals, Inc. dated November 15, 2024, is included with this filing.
Does CASI Pharmaceuticals file annual reports under Form 20-F or Form 40-F?
CASI Pharmaceuticals indicates it files annual reports under Form 20-F.
Filing Stats: 162 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-11-15 08:30:25
Filing Documents
- tm2428584d1_6k.htm (6-K) — 9KB
- tm2428584d1_ex99-1.htm (EX-99.1) — 88KB
- tm2428584d1_ex99-1img01.jpg (GRAPHIC) — 8KB
- 0001104659-24-119521.txt ( ) — 109KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: November 15, 2024